Full Papers
Impact of psoriasis remains important in psoriatic arthritis patients with low musculoskeletal disease activity
F.R. Kasiem1, M.R. Kok2, J.J. Luime3, I. Tchetverikov4, K. Wervers5, L.-A. Korswagen6, N. Denissen7, Y.P. Goekoop-Ruiterman8, M. Van Oosterhout9, F. Fodili10, J.M. Hazes11, M. Vis12
- Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands. f.kasiem@erasmusmc.nl
- Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands.
- Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
- Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Rheumatology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.
- Department of Rheumatology, Amphia Hospital, Breda, The Netherands.
- Department of Rheumatology, Haga Hospital, The Hague, The Netherlands.
- Department of Rheumatology, Groene Hart Ziekenhuis, Gouda, The Netherands.
- Department of Rheumatology, Reumazorg Zuid West Nederland, The Netherlands.
- Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
on behalf of CICERO
CER15464
2023 Vol.41, N°1
PI 0088, PF 0093
Full Papers
PMID: 35699074 [PubMed]
Received: 05/01/2022
Accepted : 28/03/2022
In Press: 13/06/2022
Published: 23/01/2023
Abstract
OBJECTIVES:
Achieving low disease activity (LDA) is important in patients with psoriatic arthritis. It is of value to know if health-related quality of life (HRQoL) of patients who reached musculoskeletal low disease activity can be further improved by additionally achieving remission of their psoriasis. So, the aim of this study was to assess HRQoL in patients with active psoriasis who reached disease activity in psoriatic arthritis (DAPSA) LDA after one year of follow-up.
METHODS:
Data were collected from the Dutch south west Psoriatic Arthritis cohort. Musculoskeletal disease activity was measured using DAPSA. Patients who reached DAPSA-LDA after one year were divided based on reaching psoriasis remission (Psoriasis Area and Severity Index [PASI] <1). HRQoL and work productivity were compared between both groups.
RESULTS:
After one year, 230 (44%) patients with active psoriasis at baseline reached DAPSA-LDA, of which 108 (47%) patients achieved psoriasis remission. The group of patients with active psoriasis (n=122, 53%) contained more men (p=0.023) and scored lower on the 12-item Psoriatic Arthritis Impact of Disease questionnaire (p=0.012). On the Skindex-17 psychosocial subscale, 31% experienced moderate to high impairment and on the symptoms subscale 28% experienced a lot of symptoms. Work productivity did not differ between both groups.
CONCLUSIONS:
The majority of patients with DAPSA-LDA and active psoriasis after one year has a good HRQoL. However, a proportion of these patients still experiences considerable skin burden. We recommend rheumatologists to continue assessing and treating psoriasis to reduce skin burden in PsA patients who achieved musculoskeletal low disease activity.
